Neurotez receives US patent for hormone Leptin
Patent issuance comes as Neurotez completes GMP manufacturing of recombinant Leptin and prepares for IND-enabling studies. Preclinical in vitro data and in vivo and interventional studies, along with
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Imfinzi (durvalumab) in combination with Padcev (enfortumab vedotin) for adult patients with muscle-invasive bladder cancer (MIBC) who cannot receive or have refused cisplatin-based chemotherapy.
ARISg and ARISj solutions are designed for collecting, assessing, distributing and managing adverse event reporting requirements of different authorities from case entry to automatic generation of submission-ready adverse
The $582,473 grant will fund research to develop Biodel’s ultra-rapid-acting insulin product candidate at high concentrations suited to provide sufficient quantities of insulin in an external artificial pancreas